[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
The interactions between leukocytes and endothelial cells have been studied extensively under conditions of ischemia and reperfusion. In contrast, attraction of leukocytes by platelets at the site of damage is poorly understood. This recruitment facilitates inflammation and atherogenesis. Studies performed ex vivo in coronary artery disease show that neutrophil-platelet adhesion increases in unstable angina, coronary angioplasty and coronary artery bypass surgery, in comparison with stable angina. Experimental works have shown the major role of platelet P-selectin in platelet-leukocyte interactions, and of fibrinogen, which is the ligand of both platelets and leukocytes (B2 integrins). Studied performed in anti-GPIIb/IIIa-treated patients demonstrate a modulation, as inhibition, of platelet-leukocyte interactions. This new drug inhibits platelet function and coagulation, and moreover inflammation.
Hézard
N
N
Laboratoire Central d'Hématologie, CNRS UPRESA 6021, CHU Robert Debré, 51092 Reims Cedex.
Metz
D
D
Garnotel
R
R
Droullé
C
C
Potron
G
G
Nguyen
P
P
D000077284:Abciximab; D000787:Angina Pectoris / Q000097:blood / Q000473:pathology; D000789:Angina, Unstable / Q000097:blood / Q000473:pathology; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology*; D018821:CD18 Antigens / Q000502:physiology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood* / Q000473:pathology / Q000601:surgery; D016207:Cytokines / Q000502:physiology; D005340:Fibrinogen / Q000502:physiology; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology / Q000627:therapeutic use; D007962:Leukocytes / Q000187:drug effects / Q000473:pathology*; D008024:Ligands; D016177:Macrophage-1 Antigen / Q000502:physiology; D008562:Membrane Glycoproteins / Q000502:physiology; D008954:Models, Biological; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D019007:P-Selectin / Q000502:physiology; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000502:physiology; D019699:Thrombospondins / Q000502:physiology; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D018821:CD18 Antigens; D016207:Cytokines; D007140:Immunoglobulin Fab Fragments; D008024:Ligands; D016177:Macrophage-1 Antigen; D008562:Membrane Glycoproteins; D019007:P-Selectin; C084882:P-selectin ligand protein; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019699:Thrombospondins; D014443:Tyrosine; D005340:Fibrinogen; D006493:Heparin; D000077466:Tirofiban; D001241:Aspirin; D000077284:Abciximab